Bortezomib and thalidomide for the first‑line treatment of multiple myeloma

Multiple myeloma (first line) - bortezomib and thalidomide: review decision April 2015 information

Multiple myeloma (first line) - bortezomib and thalidomide: appendix A - GE decision paper - March 2015 (PDF 182 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: review proposal - January 2015 information

Multiple myeloma (first line) - bortezomib and thalidomide: appendix A - matrix of stakeholders (PDF 100 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: appendix B - GE proposal paper January 2015 (PDF 318 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: equality impact assessment (PDF 69 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: final appraisal determination (post appeal) information

Multiple myeloma (first line) - bortezomib and thalidomide: final appraisal determination document (PDF 255 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: final appraisal determination - appeal decision (PDF 103 KB)

Consultee and commentator comments on the economic model from Janssen-Cilag (PDF 222 KB)

Response to consultee and commentator comments on the economic model (PDF 235 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: appeal  information

Multiple myeloma (first line) - bortezomib and thalidomide: appeal decision (PDF 115 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: notice of appeal information

Multiple myeloma (first line) - bortezomib and thalidomide: appeal registration information

Multiple myeloma (first line) - bortezomib and thalidomide: appeal announcement information

Multiple myeloma (first line) - bortezomib and thalidomide: appeal received (PDF 531 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: initial scrutiny letter (PDF 47 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: response to scrutiny letter (PDF 187 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: final scrutiny letter (PDF 25 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: final appraisal determination information

Multiple myeloma (first line) - bortezomib and thalidomide: final appraisal determination (PDF 207 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: response to comments table (PDF 305 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: consultee and commentator comments on the ACD

Multiple myeloma (first line) - bortezomib and thalidomide: manufacturer comments

Multiple myeloma (first line) - bortezomib and thalidomide: Janssen-Cilag

Multiple myeloma (first line) - bortezomib and thalidomide: Janssen-Cilag response (PDF 620 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: Janssen-Cilag additional analyses (PDF 307 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: Janssen-Cilag comments table (PDF 308 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: Celgene response (PDF 186 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: patient and professional groups

Multiple myeloma (first line) - bortezomib and thalidomide: Leukaemia CARE response (PDF 34 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: Myeloma UK response (PDF 82 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: British Society for Haematology & Royal College of Pathologists (joint submission) response (PDF 91 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: Royal College of Nursing response (PDF 63 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: Royal College of Physicians/NCRI/RCR/ACP/JCCO (joint submission) response (PDF 80 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: UK Myeloma Forum response (PDF 41 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: commentator comments

Multiple myeloma (first line) - bortezomib and thalidomide: NHS Quality Improvement Scotland (PDF 41 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: Clinical Trials Research Unit (CTRU), University of Leeds response (PDF 60 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: Southampton Health Technology Assessment Centre, University of Southampton response (PDF 58 KB)

Multiple myeloma (first line)- bortezomib and thalidomide: appraisal consultation

Multiple myeloma (first line)- bortezomib and thalidomide: appraisal consultation document information

Multiple myeloma (first line)- bortezomib and thalidomide: evaluation report

Overview (PDF 327 KB)

Assessment report

Assessment report (PDF 1.95 MB)

Response to consultee and commentator comments on the assessment report (PDF 36 KB)

Consultee and commentator comments on the assessment report

Celgene (PDF 27 KB)

Janssen Cilag (PDF 95 KB)

Leukaemia Care (PDF 59 KB)

MRC Trial Management Group (PDF 25 KB)

Myeloma UK (PDF 37 KB)

NHS Quality Improvement Scotland (PDF 26 KB)

Royal College of Pathologists (PDF 57 KB)

Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO) (PDF 40 KB)

UK Myeloma Forum (PDF 27 KB)

MMIX clarification request (PDF 58 KB)

Non-manufacturer submissions

Myeloma UK (Supported by Leukaemia CARE and Macmillan Cancer Support)

Myeloma UK (Supported by Leukaemia CARE and Macmillan Cancer Support) (PDF 1.39 MB)

Letter 1 supporting Myeloma UK statement (PDF 28 KB)

Letter 2 supporting Myeloma UK statement (PDF 21 KB)

Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO) (PDF 53 KB)

Royal College of Pathologists (PDF 57 KB)

UK Myeloma Forum (PDF 50 KB)

Manufacturer submissions

Celgene (PDF 52 KB)

Janssen Cilag (PDF 110 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: protocol (PDF 105 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: Institute's response to comments on the provisional matrix (PDF 16 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: final scope (PDF 42 KB)

Multiple myeloma (first line) - bortezomib and thalidomide: Institute's response to comments on the draft scope (PDF 122 KB)